FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will release its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. A conference call is scheduled for the same day at 5:00 PM Eastern Time to discuss the company’s corporate and financial performance. FibroGen focuses on developing innovative therapeutics, including Pamrevlumab for idiopathic pulmonary fibrosis and Roxadustat for anemia in chronic kidney disease. Roxadustat is already approved in several regions, while ongoing clinical trials aim to expand its applications. Investors can access the call via the company’s website.

Positive

• Anticipation of upcoming fourth quarter and full year 2022 financial results, which may reflect positive performance.
• Clinical development of Pamrevlumab and Roxadustat could lead to growth opportunities.

Negative

• None.

SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com. 

Contacts: FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
1.415.978.1434
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will FibroGen announce its fourth quarter and full year 2022 financial results?

FibroGen will announce its financial results on February 27, 2023, after market close.

What is the purpose of FibroGen's conference call on February 27?

The conference call will detail the company's corporate and financial performance for the fourth quarter and full year 2022.

What is the focus of FibroGen's product development?

FibroGen develops therapeutics for conditions like idiopathic pulmonary fibrosis and anemia in chronic kidney disease.

What are FibroGen's key products in clinical development?

FibroGen is developing Pamrevlumab for idiopathic pulmonary fibrosis and Roxadustat for anemia.